New electrochemical sensing technology enables detection of SARS-CoV-2 antigen-specific antibodies
Not all SARS-CoV-2 infections are created equal. We have learned this through multiple virus waves are taking their toll on the world's population.
Stay updated with breaking news from Pawan Jolly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Not all SARS-CoV-2 infections are created equal. We have learned this through multiple virus waves are taking their toll on the world's population.
The electrochemical test detects both the presence of SARS-CoV-2 RNA as well as virus antibodies in saliva.
Affordable rapid multiplexed biomarker detection at the point-of-care for patients and practitioners...
The low-cost multiplexed electrochemical biomarker detection platform will be commercialized in point-of-care diagnostics to be put into the hands of...
Today, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Australian biotech company The iQ Group Global Ltd. announced that the Institute's electrochemical eRapid technology has been licensed to Antisoma Therapeutics Pty. Ltd., a subsidiary of The iQ Group Global.